Avalo Therapeutics (AVTX) Invested Capital (2016 - 2025)
Avalo Therapeutics (AVTX) has disclosed Invested Capital for 12 consecutive years, with $91.5 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Invested Capital rose 334.37% year-over-year to $91.5 million, compared with a TTM value of $91.5 million through Sep 2025, up 334.37%, and an annual FY2024 reading of $133.4 million, up 1726.29% over the prior year.
- Invested Capital was $91.5 million for Q3 2025 at Avalo Therapeutics, down from $104.9 million in the prior quarter.
- Across five years, Invested Capital topped out at $133.4 million in Q4 2024 and bottomed at -$112.5 million in Q1 2024.
- Average Invested Capital over 5 years is $24.3 million, with a median of $14.7 million recorded in 2023.
- Peak annual rise in Invested Capital hit 1726.29% in 2024, while the deepest fall reached 1695.79% in 2024.
- Year by year, Invested Capital stood at $23.1 million in 2021, then plummeted by 147.29% to -$10.9 million in 2022, then skyrocketed by 166.92% to $7.3 million in 2023, then soared by 1726.29% to $133.4 million in 2024, then plummeted by 31.37% to $91.5 million in 2025.
- Business Quant data shows Invested Capital for AVTX at $91.5 million in Q3 2025, $104.9 million in Q2 2025, and $123.0 million in Q1 2025.